A Phase I/II clinical trial to treat dry age-related macular degeneration (Dry-AMD) is being conducted by StemCells, Inc. Dry-AMD is the most common type of macular degeneration and affects 90% of patients with the condition. It is a chronic eye disease that causes vision loss in the center of the field of vision and is the major cause of blindness and visual impairment in adults older than 50.
The treatment uses neural stem cell injections, which have been shown in animal models to preserve vision and indicates the therapeutic potential of this stem cell based treatment to reverse Dry-AMD. The first phase of this trial will determine the safety and efficacy of the potential treatment.
The clinical trial is indicative of the paradigm shift in medical treatments being driven by the unique characteristics of stem cells. To learn more about the use of stem cells in medicine and the opportunity to preserve your own stem cells to ensure your future health, visit us at www.StemSave.com or call us at 877-783-6728 (877-StemSave).
To view the clinical trial, click here.
The future of Regenerative Medicine is now™.